Scarica l'app Stockscreener
6.0519
1.92%
0.2019
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery - Yahoo Finance
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Nigeria
Taysha Gene Therapies Grants Restricted Stock Units and Stock Options to New Employees - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Taysha hires get 714,700 RSUs and 468,600 options - Stock Titan
TSHA News | TAYSHA GENE THERAPIES INC (NASDAQ:TSHA) - ChartMill
Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com
Taysha Gene Therapies Shareholders Back Governance and Leadership - TipRanks
Taysha (TSHA) director receives RSU and stock option awards, lifts holdings - Stock Titan
Taysha Gene Therapies (TSHA) director gets RSU and stock option grants - Stock Titan
Equity awards for Taysha (TSHA) director Alison S. Long detailed - Stock Titan
Taysha Gene Therapies (TSHA) director receives RSU and stock option grants - Stock Titan
Taysha Gene Therapies (NASDAQ: TSHA) holders approve board, auditor and annual say-on-pay - Stock Titan
Taysha Gene Therapies Inc Annual Shareholders Meeting Transcript - GuruFocus
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA) - Seeking Alpha
New Taysha Gene Therapies hires receive 349,000-share stock grant - Stock Titan
Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia
Taysha Gene Therapies stock hits all-time high at 5.49 USD By Investing.com - Investing.com South Africa
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
Ontario girl with Rett Syndrome denied access to promising gene therapy trial, parents say - The Globe and Mail
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 77% Upside in the Biotech Sector - DirectorsTalk Interviews
Taysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysis - MSN
Taysha (TSHA) Advances Clinical Development Strategy for TSHA-10 - GuruFocus
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Taysha Gene Therapies Q1 2026 earnings preview - MSN
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies Q1 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies Q1 2026 Earnings Call Transcript - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
1.79%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):